Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial

Lung Cancer

Volumn 74, Issue 1, 2011, Pages 75-79

  Sheikh, Hamid ^a   Colaco, Rovel ^a   Lorigan, Paul ^a   Blackhall, Fiona ^a   Califano, Raffaele ^a   Ashcroft, Linda ^a   Taylor, Paul ^a,b   Thatcher, Nicholas ^a   Faivre Finn, Corinne ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Colony stimulating factor; Concurrent chemo radiotherapy; Radiotherapy; Small cell lung cancer; Toxicity

Indexed keywords

CISPLATIN; ETOPOSIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; LUNG SMALL CELL CANCER; LUNG TOXICITY; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CISPLATIN; DISEASE PROGRESSION; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PLATELET TRANSFUSION; SMALL CELL LUNG CARCINOMA; SURVIVAL ANALYSIS; THROMBOCYTOPENIA;

EID: 80052334273     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.01.020     Document Type: Article

References (22)

1. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 1973, 4:31-42.
2. Bayman N., Sheikh H., Kularatne B., Lorigan P., Blackhall F., Thatcher N., et al. Radiotherapy for small-cell lung cancer - where are we heading?. Lung Cancer 2009, 63(3):307-314.
3. Faivre-Finn C., Lorigan P., West C., Thatcher N. Thoracic radiation therapy for limited-stage small-cell lung cancer. Unanswered questions. Clin Lung Cancer 2005, 7:23-29.
4. De Ruysscher D., Pijls-Johannesma M., Vansteenkiste J., Kester A., Rutten I., Lambin P. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol 2006, 17:543-552.
5. Fried D.B., Morris D.E., Poole C., Rosenman J.G., Halle J.S., Detterbeck F.C., et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 2004, 22:4837-4845.
6. Huncharek M., McGarry R. A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. Oncologist 2004, 9:665-672.
7. Turrisi A.T., Kim K., Blum R., Sause W.T., Livingston R.B., Komaki R., et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999, 340:265-271.
8. Faivre-Finn C., Blackhall F., Thatcher N., Taylor P., Ashcroft L., Rowbottom C., et al. Feasibility and toxicity report from a phase II study of accelerated twice-daily (BDRT) versus high dose once-daily thoracic radiotherapy (ODRT) with concurrent chemotherapy for limited stage small cell lung cancer (LS-SCLC). J Clin Oncol (Meeting Abstracts) 2008, 26:7583.
9. Smith T.J., Khatcheressian J., Lyman G.H., Ozer H., Armitage J.O., Balducci L., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 24:3187-3205.
10. Bunn P.A., Crowley J., Kelly K., Hazuka M.B., Beasley K., Upchurch C., et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 1995, 13:1632-1641.
11. http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf.
12. De Ruysscher D., Pijls-Johannesma M., Bentzen S.M., Minken A., Wanders R., Lutgens L., et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 2006, 24:1057-1063.
13. Meropol N.J., Miller L.L., Korn E.L., Braitman L.E., MacDermott M.L., Schuter L.M. Severe myelosuppression resulting from concurrent administration of G-CSF and cytotoxic chemotherapy. JNCI 1992, 84:1201-1203.
14. Ozer H., Armitage J.O., Bennett C.L., Crawford J., Demetri G.D., Pizzo P.A., et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000, 18:3558-3585.
15. Karcznmarczyk A., Nawrocki S. Toxicity of G-CSF given for neutropenia during chest radiotherapy in limited-stage small cell lung cancer (SCLC). J Clin Oncol (Meeting Abstracts) 2007, 25:18148.
16. Lilenbaum R., Samuels M., Taffaro-Neskey M., Cusnir M., Pizzolato J., Blaustein A. Phase II trial of combined modality therapy with myeloid growth factors in patients with locally advanced non-small cell lung cancer. J Thorac Oncol 2010, 5:837-840.
17. Hanna N., Neubauer M., Yiannoutsos C., McGarry R., Arseneau J., Ansari R., et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008, 26(35):5755-5760.
18. Baka S., Califano R., Ferraldeschi R., Aschroft L., Thatcher N., Taylor P., et al. Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in SCLC. Br J Cancer 2008, 99(3):442-447.
19. Hercus T., Thomas D., Guthridge M., Ekert P., King-Scott J., Parker M., et al. The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood 2009, 114(7):1289-1298.
20. Metcalf D. Haematopoietic cytokines. Blood 2008, 111(2):485-491.
21. Formenti S.C., Demaria S. Systemic effects of local radiotherapy. Lancet Oncol 2009, 10(7):18-726.
22. Faivre-Finn C., Backhall F., Snee M., Harden S., Hulse P., Lorigan P. Improving survival with thoracic radiotherapy in patients with small cell lung cancer. The CONVERT and the REST trials. Clin Oncol (R Coll Radiol) 2010, 22(7):547-549.